AC8 Stock Overview
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AusCann Group Holdings Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.04 |
| 52 Week High | AU$0.089 |
| 52 Week Low | AU$0.035 |
| Beta | 1.44 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -52.38% |
| 3 Year Change | -79.49% |
| 5 Year Change | -94.12% |
| Change since IPO | -81.82% |
Recent News & Updates
Shareholder Returns
| AC8 | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -2.6% | 0.9% |
| 1Y | -52.4% | 29.2% | 5.7% |
Return vs Industry: AC8 underperformed the Australian Pharmaceuticals industry which returned 10.2% over the past year.
Return vs Market: AC8 underperformed the Australian Market which returned -0.5% over the past year.
Price Volatility
| AC8 volatility | |
|---|---|
| AC8 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: AC8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AC8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | auscann.com.au |
AusCann Group Holdings Ltd does not have significant operations. Previously, it was engaged in the researches, develops, and commercializes various cannabinoid-derived therapeutic products. The company is headquartered in West Perth, Australia.
AusCann Group Holdings Ltd Fundamentals Summary
| AC8 fundamental statistics | |
|---|---|
| Market cap | AU$17.62m |
| Earnings (TTM) | -AU$24.94m |
| Revenue (TTM) | AU$2.04m |
8.7x
P/S Ratio-0.7x
P/E RatioIs AC8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AC8 income statement (TTM) | |
|---|---|
| Revenue | AU$2.04m |
| Cost of Revenue | AU$1.70m |
| Gross Profit | AU$336.67k |
| Other Expenses | AU$25.28m |
| Earnings | -AU$24.94m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 16.52% |
| Net Profit Margin | -1,223.99% |
| Debt/Equity Ratio | 0% |
How did AC8 perform over the long term?
See historical performance and comparison